Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts. Show more

451 D Street, Boston, MA, 02210, United States

Biotechnology

Healthcare

Market Cap

49.67M

52 Wk Range

$1.71 - $16.00

Previous Close

$1.86

Open

$1.86

Volume

689,736

Day Range

$1.86 - $2.00

Enterprise Value

40.86M

Cash

23.48M

Avg Qtr Burn

-8.165M

Insider Ownership

26.98%

Institutional Own.

16.25%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ELI-002 7P Details Pancreatic cancer, Cancer	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELI-002 2P Details Solid tumor/s, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELI-002 7P (KRAS Vaccine) Details Metastatic Pancreatic Ductal Adenocarcinoma, Cancer	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.